International Myeloma Foundation Says FDA Approval of Bristol Myers Squibb’s and bluebird bio's CAR T-Cell Immunotherapy Treatment for Multiple Myeloma Is Welcome News for Patients (https://www.myeloma.org/fda-approval-abecma-idecabtagene-vicleucel)